Alzamend Neuro (ALZN) Total Liabilities (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Total Liabilities came in at $1.3 million in Q2 2026, up 112.07% year-over-year from $634761.0 in Q2 2025, and down 27.52% quarter-over-quarter from $1.9 million in Q1 2026.
Analysis
Alzamend Neuro (ALZN) Total Liabilities (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Total Liabilities across 7 years of filings, most recently posting $1.3 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 112.07% year-over-year to $1.3 million; the TTM figure through Apr 2026 stood at $1.3 million (up 112.07% YoY), while the FY2026 annual figure was $1.3 million, up 112.07% from the prior year.
- Total Liabilities came in at $1.3 million for Q2 2026 at Alzamend Neuro, down from $1.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $4.6 million in Q1 2024 to a low of $466977.0 in Q1 2022.
- Average Total Liabilities over 5 years is $1.9 million, with a median of $1.5 million recorded in 2022.
- Year-over-year, Total Liabilities soared 465.87% in 2023 and sank 84.11% in 2025.
- Over 5 years, Total Liabilities stood at $1.6 million in 2022, then jumped by 123.89% to $3.7 million in 2023, then sank by 65.77% to $1.3 million in 2024, then sank by 42.82% to $717488.0 in 2025, then soared by 87.62% to $1.3 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $1.3 million in Q2 2026, $1.9 million in Q1 2026, and $717488.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.68 Bn | 193.69 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 131.05 Bn | 123.20 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.80 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.99 Bn | 55.81 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 53.41 Bn | 48.27 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.72 Bn | 30.43 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.53 Bn | 29.53 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | 1.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 1.35 Mn |
| Jan 31, 2026 | 1.86 Mn |
| Oct 31, 2025 | 717,488.00 |
| Jul 31, 2025 | 983,311.00 |
| Apr 30, 2025 | 634,761.00 |
| Jan 31, 2025 | 725,851.00 |
| Oct 31, 2024 | 1.25 Mn |
| Jul 31, 2024 | 2.88 Mn |
| Apr 30, 2024 | 3.23 Mn |
| Jan 31, 2024 | 4.57 Mn |
| Oct 31, 2023 | 3.67 Mn |
| Jul 31, 2023 | 2.74 Mn |
| Apr 30, 2023 | 2.87 Mn |
| Jan 31, 2023 | 2.64 Mn |
| Oct 31, 2022 | 1.64 Mn |
| Jul 31, 2022 | 1.03 Mn |
| Apr 30, 2022 | 1.16 Mn |
| Jan 31, 2022 | 466,977.00 |
| Oct 31, 2021 | 1.48 Mn |
| Jul 31, 2021 | 1.47 Mn |